Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Impact in
- Oncology 384
Classified as
- Journal
- PubMed
In The Last Decade
doi.org/w59391831 →Countries where authors are citing Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
This map shows the geographic impact of Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. more than expected).
Fields of papers citing Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
This network shows the impact of Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers..
About Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
This paper, published in 1995, received 1.2k indexed citations . Written by James G. Herman, Adrian Merlo, Li Mao, Rena G. Lapidus, Jean‐Pierre J. Issa, Nancy E. Davidson, David Sidransky and Stephen B. Baylin covering the research area of Molecular Biology. It is primarily cited by scholars working on Molecular Biology (839 citations), Oncology (384 citations), Cancer Research (189 citations), Pathology and Forensic Medicine (145 citations) and Genetics (115 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w59391831.